Literature DB >> 15177849

Macrolide resistance in Streptococci and Haemophilus influenzae.

Bülent Bozdogan1, Peter C Appelbaum.   

Abstract

Antimicrobial resistance is a growing problem among pathogens from respiratory tract infections. b-Lactam resistance rates are escalating among Streptococcus pneumoniae and Haemophilus influenzae. Macrolides are increasingly used for the treatment of respiratory tract infections, but their utility is compromised by intrinsic and acquired resistance. This article analyses macrolide-resistance mechanisms and their worldwide distributions in S pneumoniae, S pyogenes, and H influenzae.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177849     DOI: 10.1016/j.cll.2004.03.006

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  5 in total

Review 1.  Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus.

Authors:  James M Musser; Frank R DeLeo
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

2.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 3.  The use of macrolides in treatment of upper respiratory tract infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel DeCorby; George G Zhanel
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

4.  The Use of Macrolides in Treatment of Upper Respiratory Tract Infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel Decorby; George G Zhanel
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

5.  No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  BMC Infect Dis       Date:  2015-11-13       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.